Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report

PURPOSE: HER2 mutations are identified in approximately 2% of non-small-cell lung cancer (NSCLC) cases; however, until now, there are no approved standard targeted therapy for NSCLC patients harboring HER2 mutations. CASE PRESENTATION: We present a 63-year-old male with a long smoking history, who w...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Lin, Ling, Ge, Hongfei, Yan, Zhengqing, Wang, Guoqiang, Wu, Xiaomai, Lv, Dongqing
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2019
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6913761/
https://ncbi.nlm.nih.gov/pubmed/31849493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S228726
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller